HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
Guzman Y Gomez’s outlook unchanged despite strong update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,869.00 | 52.50 | -0.59% |
| CAC 40 | 7,873.11 | 45.48 | 0.58% |
| DAX 40 | 25,298.61 | 38.71 | 0.15% |
| Dow JONES (US) | 51,621.48 | 48.62 | -0.09% |
| FTSE 100 | 10,724.86 | 74.53 | 0.70% |
| HKSE | 24,314.17 | 31.05 | -0.13% |
| NASDAQ | 26,692.87 | 511.51 | -1.88% |
| Nikkei 225 | 67,744.29 | 33.23 | -0.05% |
| NZX 50 Index | 13,760.39 | 10.79 | 0.08% |
| S&P 500 | 7,718.94 | 86.51 | -1.11% |
| S&P/ASX 200 | 8,727.90 | 56.00 | -0.64% |
| SSE Composite Index | 3,767.23 | 33.64 | -0.88% |